MRVI 📈 Maravai Lifesciences - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US56600D1072
MRVI: Nucleic Acids, Antibodies, Enzymes, Oligonucleotides, ELISA Kits, Reagents
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California. Web URL: https://www.maravai.com
Additional Sources for MRVI Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MRVI Stock Overview
Market Cap in USD | 1,275m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2020-11-20 |
MRVI Stock Ratings
Growth 5y | -78.6% |
Fundamental | 13.8% |
Dividend | - |
Rel. Strength Industry | -405 |
Analysts | 4.07/5 |
Fair Price Momentum | 3.97 USD |
Fair Price DCF | 11.07 USD |
MRVI Dividends
No Dividends PaidMRVI Growth Ratios
Growth Correlation 3m | -78.8% |
Growth Correlation 12m | 4.3% |
Growth Correlation 5y | -90% |
CAGR 5y | -34.25% |
CAGR/Mean DD 5y | -0.59 |
Sharpe Ratio 12m | 0.18 |
Alpha | -39.26 |
Beta | 0.74 |
Volatility | 74.41% |
Current Volume | 2471.1k |
Average Volume 20d | 1686k |
What is the price of MRVI stocks?
As of December 21, 2024, the stock is trading at USD 5.37 with a total of 2,471,117 shares traded.
Over the past week, the price has changed by -5.29%, over one month by +11.41%, over three months by -36.37% and over the past year by -15.70%.
As of December 21, 2024, the stock is trading at USD 5.37 with a total of 2,471,117 shares traded.
Over the past week, the price has changed by -5.29%, over one month by +11.41%, over three months by -36.37% and over the past year by -15.70%.
Is Maravai Lifesciences a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Maravai Lifesciences is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 13.76 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MRVI as of December 2024 is 3.97. This means that MRVI is currently overvalued and has a potential downside of -26.07%.
Neither. Based on ValueRay Fundamental Analyses, Maravai Lifesciences is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 13.76 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MRVI as of December 2024 is 3.97. This means that MRVI is currently overvalued and has a potential downside of -26.07%.
Is MRVI a buy, sell or hold?
Maravai Lifesciences has received a consensus analysts rating of 4.07. Therefor, it is recommend to buy MRVI.
Maravai Lifesciences has received a consensus analysts rating of 4.07. Therefor, it is recommend to buy MRVI.
- Strong Buy: 8
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 0
What are the forecast for MRVI stock price target?
According to ValueRays Forecast Model, MRVI Maravai Lifesciences will be worth about 4.3 in December 2025. The stock is currently trading at 5.37. This means that the stock has a potential downside of -20.3%.
According to ValueRays Forecast Model, MRVI Maravai Lifesciences will be worth about 4.3 in December 2025. The stock is currently trading at 5.37. This means that the stock has a potential downside of -20.3%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 9.5 | 76.9% |
Analysts Target Price | 13 | 142.1% |
ValueRay Target Price | 4.3 | -20.3% |